Boston Scientific is trading 5.33% higher at $45.82, with broader market sentiment the clearest explanation for the gain.

  • Major U.S. indexes are also sharply higher as election uncertainty eases.
  • The company announced a $455 million Blackstone partnership to fund development of its VITALYST heart pump.
  • Early WATCHMAN FLX Pro trial data were positive, but available reports do not establish either company update as the direct cause of the gain.